Life Science Business of Merck KGaA, Darmstadt, Germany Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers
- 87% of respondents deemed mRNA a key modality for the future
- More than 60% of vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
- Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption
Burlington, Massachusetts, May 31, 2023 – According to a recent study sponsored by the Life Science business of Merck KGaA, Darmstadt, Germany, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.
“Vaccine manufacturers in APAC are looking to build capacity for mRNA technology over the next two to three years, while continuing to produce both traditional and modern cell-based vaccines,” said Josephine Cheng, Senior Consultant, Process Solutions APAC at the Life Science business sector of Merck KGaA, Darmstadt, Germany. “Across APAC, governments are investing and supportive of driving therapeutic discovery and manufacturing. With the range of tools we offer, we can better equip vaccine manufacturers to treat the regional and global population.”
The study interviewed vaccine manufacturers across APAC, including research institutes, pharmaceutical and biotech companies. Eighty-seven percent deemed mRNA a promising technology, expecting it to be a key modality in the future. This is based on the perception that the mRNA platform benefits from shorter development time and templated manufacturing processes, proven efficacy, lower biohazard risk for operators, and flexibility in covering different types of diseases and variants.
Japan, South Korea, Australia, Indonesia, Singapore, China, and India are among the markets actively exploring to develop mRNA technology. Over sixty percent of the vaccine makers prefer to revamp or establish new facilities especially for mRNA with expansion planned over the next two to three years.
To effectively move mRNA forward, respondents highlighted the need for skilled personnel trained in these new technologies, tech-transfer expertise, a reliable supply chain, and mRNA-specific regulatory guidelines.
The Life Science business of Merck KGaA, Darmstadt, Germany‘s contribution to future vaccine manufacturing
The Life Science business of Merck KGaA, Darmstadt, Germany supports mRNA manufacturers helping accelerate speed to market, ensuring safety and efficacy, to reducing complexity across the entire mRNA process to help accelerate delivery of mRNA vaccines to patients worldwide. More information is available on sigmaaldrich.com/vaccines
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
We successfully integrated p-Chip's microtransponder technology as a crypto-anchor into a cyber-physical trust framework solution developed by us.